The generic name of Gizumab is sofosbuvir vipatasvir tablets. If the administration of sofosbuvir vipatasvir tablets results in mild elevation of uric acid, it can be improved by adjusting the dosage of the medication and drinking plenty of fluids. If the administration of sofosbuvir vipatasvir tablets results in a serious increase in uric acid, the drug should be discontinued if necessary. Sofosbuvir vipatasvir tablets have antiviral effects and are mainly indicated for the treatment of chronic hepatitis C virus infection in adults. Adverse effects of sofosbuvir vipatasvir tablets mainly include headache, fatigue, nausea, weakness, insomnia. If patients with the drug caused a mild increase in uric acid levels, usually patients can follow the doctor’s instructions to adjust the dosage of sofosbuvir vipatasvir tablets, daily can also be appropriate to increase the amount of water consumption, appropriate exercise, etc., to promote uric acid metabolism, in order to reduce the impact on the body. If the uric acid level is persistently or severely elevated after the use of the drug, the patient should stop using sofosbuvir vipatasvir tablets if necessary, and may also take other drugs as prescribed by the doctor for alternative treatment. This drug is contraindicated in persons who have developed hypersensitivity to the active ingredient or to any of the excipients. CAUTION: Coadministration with amiodarone is contraindicated and may result in severe symptomatic bradycardia. Patients are advised to take Sofosbuvir Vipatasvir Tablets under the supervision of a physician. Attention should be paid to regular medical review during the medication period in order to monitor the health condition.